Literature DB >> 19261796

Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.

Timothy J Kidd1, Kay A Ramsay, Honghua Hu, Peter T P Bye, Mark R Elkins, Keith Grimwood, Colin Harbour, Guy B Marks, Michael D Nissen, Philip J Robinson, Barbara R Rose, Theo P Sloots, Claire E Wainwright, Scott C Bell.   

Abstract

Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct identification ensures effective patient management and infection control strategies. However, little is known about how often CF sputum isolates are falsely identified as P. aeruginosa. We used P. aeruginosa-specific duplex real-time PCR assays to determine if 2,267 P. aeruginosa sputum isolates from 561 CF patients were correctly identified by 17 Australian clinical microbiology laboratories. Misidentified isolates underwent further phenotypic tests, amplified rRNA gene restriction analysis, and partial 16S rRNA gene sequence analysis. Participating laboratories were surveyed on how they identified P. aeruginosa from CF sputum. Overall, 2,214 (97.7%) isolates from 531 (94.7%) CF patients were correctly identified as P. aeruginosa. Further testing with the API 20NE kit correctly identified only 34 (59%) of the misidentified isolates. Twelve (40%) patients had previously grown the misidentified species in their sputum. Achromobacter xylosoxidans (n = 21), Stenotrophomonas maltophilia (n = 15), and Inquilinus limosus (n = 4) were the species most commonly misidentified as P. aeruginosa. Overall, there were very low rates of P. aeruginosa misidentification among isolates from a broad cross section of Australian CF patients. Additional improvements are possible by undertaking a culture history review, noting colonial morphology, and performing stringent oxidase, DNase, and colistin susceptibility testing for all presumptive P. aeruginosa isolates. Isolates exhibiting atypical phenotypic features should be evaluated further by additional phenotypic or genotypic identification techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261796      PMCID: PMC2681828          DOI: 10.1128/JCM.00014-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Emergence of new pathogens in CF: the devil we know or the devil we don't know?

Authors:  Jane L Burns
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

2.  Use of 16S rRNA gene sequencing for identification of nonfermenting gram-negative bacilli recovered from patients attending a single cystic fibrosis center.

Authors:  Agnes Ferroni; Isabelle Sermet-Gaudelus; Eric Abachin; Gilles Quesne; Gerard Lenoir; Patrick Berche; Jean-Louis Gaillard
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 3.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

4.  Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  L Saiman; Y Chen; S Tabibi; P San Gabriel; J Zhou; Z Liu; L Lai; S Whittier
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

7.  Genomovar diversity amongst Burkholderia cepacia complex isolates from an Australian adult cystic fibrosis unit.

Authors:  T J Kidd; S C Bell; C Coulter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-27       Impact factor: 3.267

8.  Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic.

Authors:  David S Armstrong; Gillian M Nixon; Rosemary Carzino; Andrea Bigham; John B Carlin; Roy M Robins-Browne; Keith Grimwood
Journal:  Am J Respir Crit Care Med       Date:  2002-10-01       Impact factor: 21.405

9.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

10.  Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.

Authors:  Xuan Qin; Julia Emerson; Jenny Stapp; Lynn Stapp; Patrick Abe; Jane L Burns
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

View more
  21 in total

1.  A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.

Authors:  Frank Guarnieri; Jean L Spencer; Edgar C Lucey; Matthew A Nugent; Phillip J Stone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

3.  Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Authors:  J Manos; H Hu; B R Rose; C E Wainwright; I B Zablotska; J Cheney; L Turnbull; C B Whitchurch; K Grimwood; C Harmer; S N Anuj; C Harbour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-07       Impact factor: 3.267

4.  Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosis.

Authors:  Timothy J Kidd; Keith Grimwood; Kay A Ramsay; Paul B Rainey; Scott C Bell
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

5.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

6.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

Review 7.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

8.  Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.

Authors:  Lois W Martin; Cynthia L Robson; Annabelle M Watts; Andrew R Gray; Claire E Wainwright; Scott C Bell; Kay A Ramsay; Timothy J Kidd; David W Reid; Ben Brockway; Iain L Lamont
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis.

Authors:  Florence Le Gall; Rozenn Le Berre; Sylvain Rosec; Jeanne Hardy; Stéphanie Gouriou; Sylvie Boisramé-Gastrin; Sophie Vallet; Gilles Rault; Christopher Payan; Geneviève Héry-Arnaud
Journal:  BMC Microbiol       Date:  2013-06-21       Impact factor: 3.605

10.  Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological setting.

Authors:  Timothy J Kidd; Stephen R Ritchie; Kay A Ramsay; Keith Grimwood; Scott C Bell; Paul B Rainey
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.